Mineralys Therapeutics (MLYS) Liabilities and Shareholders Equity (2022 - 2026)

Mineralys Therapeutics (MLYS) has 5 years of Liabilities and Shareholders Equity data on file, last reported at $652.9 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 83.94% year-over-year to $652.9 million; the trailing twelve-month figure through Mar 2026 stood at $2.3 billion (up 96.09% YoY), and the FY2025 full-year result was $661.8 million, up 221.42% from the prior year.
• Liabilities and Shareholders Equity fell to $652.9 million in Q1 2026, from $661.8 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $661.8 million in Q4 2025 to a low of $114.4 million in Q4 2022.
• A 5-year average of $356.2 million and a median of $312.5 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity declined 18.17% in 2024 and surged 221.42% in 2025, its largest moves.
• Tracing MLYS's Liabilities and Shareholders Equity over 5 years: stood at $114.4 million in 2022, then surged by 119.88% to $251.6 million in 2023, then retreated by 18.17% to $205.9 million in 2024, then surged by 221.42% to $661.8 million in 2025, then decreased by 1.35% to $652.9 million in 2026.
• Business Quant data shows MLYS's Liabilities and Shareholders Equity at $652.9 million in Q1 2026, $661.8 million in Q4 2025, and $599.9 million in Q3 2025.